David Katz Quotes on Competition (2 Quotes)

Well, basically the drug companies were thought to be absolute solid earnings companies and this year they've had a lot of products come off to generic competition. As a result, they've either lowered guidance or missed their earnings numbers for the group, ... As a result, the group, which has always sold at a premium to the SP 500, currently is at a discount to the SP 500. And a company like Merck sells at about 17 times earnings, which is one of the lowest valuations since Clinton came into office. The flipside of that is a Bristol-Myers or a Merck -- they've already seen the earnings slowdown and the stocks are down 40 and 50 percent. Many of them are getting to levels that you really can start to buy.

we do think the housing market is going to be okay. It's not going to fall off a cliff. That environment will be quite good for Shaw and they're picking up a lot of market share, versus competition.